AU2008220572B2 - Improved medicinal compositions comprising buprenorphine and nalmefene - Google Patents

Improved medicinal compositions comprising buprenorphine and nalmefene Download PDF

Info

Publication number
AU2008220572B2
AU2008220572B2 AU2008220572A AU2008220572A AU2008220572B2 AU 2008220572 B2 AU2008220572 B2 AU 2008220572B2 AU 2008220572 A AU2008220572 A AU 2008220572A AU 2008220572 A AU2008220572 A AU 2008220572A AU 2008220572 B2 AU2008220572 B2 AU 2008220572B2
Authority
AU
Australia
Prior art keywords
buprenorphine
nalmefene
composition
patient
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008220572A
Other languages
English (en)
Other versions
AU2008220572A1 (en
Inventor
Christopher Bourne Chapleo
Neil Hyde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indivior UK Ltd
Original Assignee
Indivior UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indivior UK Ltd filed Critical Indivior UK Ltd
Publication of AU2008220572A1 publication Critical patent/AU2008220572A1/en
Assigned to RB PHARMACEUTICALS LIMITED reassignment RB PHARMACEUTICALS LIMITED Request for Assignment Assignors: RECKITT BENCKISER HEALTHCARE (UK) LIMITED
Application granted granted Critical
Publication of AU2008220572B2 publication Critical patent/AU2008220572B2/en
Assigned to INDIVIOR UK LIMITED reassignment INDIVIOR UK LIMITED Request to Amend Deed and Register Assignors: RB PHARMACEUTICALS LIMITED
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2008220572A 2007-03-01 2008-02-15 Improved medicinal compositions comprising buprenorphine and nalmefene Ceased AU2008220572B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0703933.2 2007-03-01
GB0703933A GB2447013A (en) 2007-03-01 2007-03-01 Analgesic composition containing buprenorphone and nalmefene
PCT/GB2008/000522 WO2008104736A1 (en) 2007-03-01 2008-02-15 Improved medicinal compositions comprising buprenorphine and nalmefene

Publications (2)

Publication Number Publication Date
AU2008220572A1 AU2008220572A1 (en) 2008-09-04
AU2008220572B2 true AU2008220572B2 (en) 2014-03-27

Family

ID=37965707

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008220572A Ceased AU2008220572B2 (en) 2007-03-01 2008-02-15 Improved medicinal compositions comprising buprenorphine and nalmefene

Country Status (21)

Country Link
US (1) US8497280B2 (enExample)
EP (1) EP2114452B1 (enExample)
JP (1) JP5577102B2 (enExample)
KR (1) KR101437461B1 (enExample)
CN (1) CN101622012B (enExample)
AR (1) AR065582A1 (enExample)
AU (1) AU2008220572B2 (enExample)
BR (1) BRPI0807903A2 (enExample)
CA (1) CA2678568C (enExample)
CL (1) CL2008000607A1 (enExample)
DK (1) DK2114452T3 (enExample)
ES (1) ES2476865T3 (enExample)
GB (1) GB2447013A (enExample)
HR (1) HRP20140591T1 (enExample)
MX (1) MX2009009134A (enExample)
PE (2) PE20120956A1 (enExample)
PL (1) PL2114452T3 (enExample)
PT (1) PT2114452E (enExample)
TW (1) TWI468163B (enExample)
WO (1) WO2008104736A1 (enExample)
ZA (1) ZA200905692B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
EA019331B1 (ru) * 2009-05-25 2014-02-28 Х. Лундбекк А/С Получение налмефена гидрохлорида из налтрексона
ES2716570T3 (es) 2012-04-17 2019-06-13 Purdue Pharma Lp Sistemas y procedimientos para tratar o prevenir una respuesta farmacodinámica adversa inducida por opioides
CN103637983B (zh) * 2013-12-16 2017-08-04 科贝源(北京)生物医药科技有限公司 一种含有盐酸纳美芬的药物组合物及其制备方法
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN104922061B (zh) * 2015-05-26 2017-09-22 成都天台山制药有限公司 盐酸纳美芬注射液药物组合物和制法
JP2020526500A (ja) 2017-06-30 2020-08-31 パーデュー、ファーマ、リミテッド、パートナーシップ 治療方法及びその剤形
JP2021515034A (ja) * 2018-02-22 2021-06-17 アビオール、インコーポレイテッド 経粘膜フィルム組成物ならびにそれを作製及び使用する方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004178A1 (en) * 1999-11-19 2003-01-02 Christopher Bourne Chapleo Analgesic compositions containing buprenorphine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
US9539303B2 (en) * 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
WO2008088331A1 (en) * 2007-01-19 2008-07-24 Gloucester Pharmaceuticals Methods for increasing levels of human fetal hemoglobin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004178A1 (en) * 1999-11-19 2003-01-02 Christopher Bourne Chapleo Analgesic compositions containing buprenorphine

Also Published As

Publication number Publication date
WO2008104736A1 (en) 2008-09-04
PE20120956A1 (es) 2012-08-01
EP2114452B1 (en) 2014-04-09
MX2009009134A (es) 2009-09-03
CA2678568C (en) 2015-06-16
ES2476865T3 (es) 2014-07-15
PE20090625A1 (es) 2009-06-04
CN101622012A (zh) 2010-01-06
TW200900067A (en) 2009-01-01
JP2010520184A (ja) 2010-06-10
HK1139868A1 (en) 2010-09-30
HRP20140591T1 (hr) 2014-09-12
GB2447013A (en) 2008-09-03
AR065582A1 (es) 2009-06-17
KR20090115862A (ko) 2009-11-09
EP2114452A1 (en) 2009-11-11
CA2678568A1 (en) 2008-09-04
CL2008000607A1 (es) 2008-10-03
US8497280B2 (en) 2013-07-30
BRPI0807903A2 (pt) 2014-06-17
ZA200905692B (en) 2010-10-27
PL2114452T3 (pl) 2014-09-30
GB0703933D0 (en) 2007-04-11
JP5577102B2 (ja) 2014-08-20
AU2008220572A1 (en) 2008-09-04
KR101437461B1 (ko) 2014-09-05
DK2114452T3 (da) 2014-06-30
CN101622012B (zh) 2012-05-30
US20100152222A1 (en) 2010-06-17
TWI468163B (zh) 2015-01-11
PT2114452E (pt) 2014-07-15

Similar Documents

Publication Publication Date Title
CA2678481C (en) Improved medicinal compositions comprising buprenorphine and naltrexone
TWI451868B (zh) 醫藥組成物之改良及相關之改良
CA2678568C (en) Improved medicinal compositions comprising buprenorphine and nalmefene
AU2014201782A1 (en) Improved medicinal compositions comprising buprenorphine and naltrexone
AU2014201777A1 (en) Improvements in and relating to medicinal compositions
HK1139868B (en) Improved medicinal compositions comprising buprenorphine and nalmefene
HK1139867A (en) Improved medicinal compositions comprising buprenorphine and naltrexone
HK1139871B (en) Improvements in and relating to medicinal compositions

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: RB PHARMACEUTICALS LIMITED

Free format text: FORMER APPLICANT(S): RECKITT BENCKISER HEALTHCARE (UK) LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired